{"id":"NCT04246554","sponsor":"University Hospitals Cleveland Medical Center","briefTitle":"Ketorolac as an Adjuvant Agent for Postoperative Pain Control Following Arthroscopic ACL Surgery","officialTitle":"Ketorolac as an Adjuvant Agent for Postoperative Pain Control Following Arthroscopic ACL Surgery","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-05-21","primaryCompletion":"2020-10-09","completion":"2021-01-01","firstPosted":"2020-01-29","resultsPosted":"2021-12-21","lastUpdate":"2021-12-21"},"enrollment":49,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["ACL Injury","Postoperative Pain"],"interventions":[{"type":"DRUG","name":"Ketorolac","otherNames":[]},{"type":"DRUG","name":"Oxycodone-Acetaminophen","otherNames":[]}],"arms":[{"label":"Control","type":"EXPERIMENTAL"},{"label":"Ketorolac","type":"EXPERIMENTAL"}],"summary":"1. The investigators aim to examine the use of IV and oral ketorolac as an adjunctive agent to the standard of care pain protocol for postoperative pain control following ACL reconstruction surgery.\n2. The investigators hypothesize that the use of IV and oral ketorolac in addition to the standard of care pain protocol will reduce postoperative opioid consumption following ACL reconstruction surgery.","primaryOutcome":{"measure":"Postoperative Visual Analogue Scale Scores","timeFrame":"Up to 8 weeks postoperative","effectByArm":[{"arm":"Control","deltaMin":50.4,"sd":5.3},{"arm":"Ketorolac","deltaMin":40,"sd":4.9}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":2,"exclusionCount":9},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["36476466"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":26},"commonTop":["drowsy","nausea/ vomitin","constipation","dizzy","indigestion"]}}